Occupancy of Dopamine D3 and D2 Receptors by Buspirone

A [11C]-(+)-PHNO PET Study in Humans

Bernard Le Foll, Doris Payer, Patricia Di Ciano, Mihail Guranda, Shinichiro Nakajima, Junchao Tong, Esmaeil Mansouri, Alan A. Wilson, Sylvain Houle, Jeff H. Meyer, Ariel Graff-Guerrero, Isabelle Boileau

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There is considerable interest in blocking the dopamine D3 receptor (DRD3) versus the D2 receptor (DRD2) to treat drug addiction. However, there are currently no selective DRD3 antagonists available in the clinic. The anxiolytic drug buspirone has been proposed as a potential strategy as findings suggest that this drug has high in vitro affinity for DRD3, binds to DRD3 in brain of living non-human primate, and also disrupts psychostimulant self-administration in preclinical models. No study has explored the occupancy of DRD3 by buspirone in humans. Here, we used positron emission tomography (PET) and the D3 -preferring probe, [11C]-(+)-PHNO, to test the hypothesis that buspirone will occupy (decreases [11C]-(+)-PHNO binding) the DRD3 more readily than the DRD2. Eight healthy participants underwent [11C]-(+)-PHNO scans after single oral dose administration of placebo and 30, 60, and 120 mg of buspirone in a single-blind within-subjects design. [11C]-(+)-PHNO binding in DRD2- and DRD3-rich areas was decreased by the highest (60-120 mg), but not the lowest (30 mg), doses of buspirone. The maximal occupancy obtained was ∼25% in both areas. Plasma levels of prolactin (a DRD2 marker) correlated with percentage occupancy after orally administered buspirone. Self-reported dizziness and drowsiness increased after buspirone but that did not correlate with receptor occupancy in any region. Overall, the modest occupancy of DRD2 and DRD3 even at high acute doses of buspirone, yielding high levels of metabolites, suggests that buspirone may not be a good drug to preferentially block DRD3 in humans.

Original languageEnglish
Pages (from-to)529-537
Number of pages9
JournalNeuropsychopharmacology
Volume41
Issue number2
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Dopamine D3 Receptors
Buspirone
Dopamine D2 Receptors
Positron-Emission Tomography
Pharmaceutical Preparations
naxagolide
Self Administration
Sleep Stages
Anti-Anxiety Agents
Dizziness
Prolactin
Primates
Substance-Related Disorders
Oral Administration
Healthy Volunteers
Placebos

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Occupancy of Dopamine D3 and D2 Receptors by Buspirone : A [11C]-(+)-PHNO PET Study in Humans. / Le Foll, Bernard; Payer, Doris; Di Ciano, Patricia; Guranda, Mihail; Nakajima, Shinichiro; Tong, Junchao; Mansouri, Esmaeil; Wilson, Alan A.; Houle, Sylvain; Meyer, Jeff H.; Graff-Guerrero, Ariel; Boileau, Isabelle.

In: Neuropsychopharmacology, Vol. 41, No. 2, 01.01.2016, p. 529-537.

Research output: Contribution to journalArticle

Le Foll, B, Payer, D, Di Ciano, P, Guranda, M, Nakajima, S, Tong, J, Mansouri, E, Wilson, AA, Houle, S, Meyer, JH, Graff-Guerrero, A & Boileau, I 2016, 'Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans', Neuropsychopharmacology, vol. 41, no. 2, pp. 529-537. https://doi.org/10.1038/npp.2015.177
Le Foll, Bernard ; Payer, Doris ; Di Ciano, Patricia ; Guranda, Mihail ; Nakajima, Shinichiro ; Tong, Junchao ; Mansouri, Esmaeil ; Wilson, Alan A. ; Houle, Sylvain ; Meyer, Jeff H. ; Graff-Guerrero, Ariel ; Boileau, Isabelle. / Occupancy of Dopamine D3 and D2 Receptors by Buspirone : A [11C]-(+)-PHNO PET Study in Humans. In: Neuropsychopharmacology. 2016 ; Vol. 41, No. 2. pp. 529-537.
@article{e20bd39d905a47708bac6c83d783cd34,
title = "Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans",
abstract = "There is considerable interest in blocking the dopamine D3 receptor (DRD3) versus the D2 receptor (DRD2) to treat drug addiction. However, there are currently no selective DRD3 antagonists available in the clinic. The anxiolytic drug buspirone has been proposed as a potential strategy as findings suggest that this drug has high in vitro affinity for DRD3, binds to DRD3 in brain of living non-human primate, and also disrupts psychostimulant self-administration in preclinical models. No study has explored the occupancy of DRD3 by buspirone in humans. Here, we used positron emission tomography (PET) and the D3 -preferring probe, [11C]-(+)-PHNO, to test the hypothesis that buspirone will occupy (decreases [11C]-(+)-PHNO binding) the DRD3 more readily than the DRD2. Eight healthy participants underwent [11C]-(+)-PHNO scans after single oral dose administration of placebo and 30, 60, and 120 mg of buspirone in a single-blind within-subjects design. [11C]-(+)-PHNO binding in DRD2- and DRD3-rich areas was decreased by the highest (60-120 mg), but not the lowest (30 mg), doses of buspirone. The maximal occupancy obtained was ∼25{\%} in both areas. Plasma levels of prolactin (a DRD2 marker) correlated with percentage occupancy after orally administered buspirone. Self-reported dizziness and drowsiness increased after buspirone but that did not correlate with receptor occupancy in any region. Overall, the modest occupancy of DRD2 and DRD3 even at high acute doses of buspirone, yielding high levels of metabolites, suggests that buspirone may not be a good drug to preferentially block DRD3 in humans.",
author = "{Le Foll}, Bernard and Doris Payer and {Di Ciano}, Patricia and Mihail Guranda and Shinichiro Nakajima and Junchao Tong and Esmaeil Mansouri and Wilson, {Alan A.} and Sylvain Houle and Meyer, {Jeff H.} and Ariel Graff-Guerrero and Isabelle Boileau",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/npp.2015.177",
language = "English",
volume = "41",
pages = "529--537",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Occupancy of Dopamine D3 and D2 Receptors by Buspirone

T2 - A [11C]-(+)-PHNO PET Study in Humans

AU - Le Foll, Bernard

AU - Payer, Doris

AU - Di Ciano, Patricia

AU - Guranda, Mihail

AU - Nakajima, Shinichiro

AU - Tong, Junchao

AU - Mansouri, Esmaeil

AU - Wilson, Alan A.

AU - Houle, Sylvain

AU - Meyer, Jeff H.

AU - Graff-Guerrero, Ariel

AU - Boileau, Isabelle

PY - 2016/1/1

Y1 - 2016/1/1

N2 - There is considerable interest in blocking the dopamine D3 receptor (DRD3) versus the D2 receptor (DRD2) to treat drug addiction. However, there are currently no selective DRD3 antagonists available in the clinic. The anxiolytic drug buspirone has been proposed as a potential strategy as findings suggest that this drug has high in vitro affinity for DRD3, binds to DRD3 in brain of living non-human primate, and also disrupts psychostimulant self-administration in preclinical models. No study has explored the occupancy of DRD3 by buspirone in humans. Here, we used positron emission tomography (PET) and the D3 -preferring probe, [11C]-(+)-PHNO, to test the hypothesis that buspirone will occupy (decreases [11C]-(+)-PHNO binding) the DRD3 more readily than the DRD2. Eight healthy participants underwent [11C]-(+)-PHNO scans after single oral dose administration of placebo and 30, 60, and 120 mg of buspirone in a single-blind within-subjects design. [11C]-(+)-PHNO binding in DRD2- and DRD3-rich areas was decreased by the highest (60-120 mg), but not the lowest (30 mg), doses of buspirone. The maximal occupancy obtained was ∼25% in both areas. Plasma levels of prolactin (a DRD2 marker) correlated with percentage occupancy after orally administered buspirone. Self-reported dizziness and drowsiness increased after buspirone but that did not correlate with receptor occupancy in any region. Overall, the modest occupancy of DRD2 and DRD3 even at high acute doses of buspirone, yielding high levels of metabolites, suggests that buspirone may not be a good drug to preferentially block DRD3 in humans.

AB - There is considerable interest in blocking the dopamine D3 receptor (DRD3) versus the D2 receptor (DRD2) to treat drug addiction. However, there are currently no selective DRD3 antagonists available in the clinic. The anxiolytic drug buspirone has been proposed as a potential strategy as findings suggest that this drug has high in vitro affinity for DRD3, binds to DRD3 in brain of living non-human primate, and also disrupts psychostimulant self-administration in preclinical models. No study has explored the occupancy of DRD3 by buspirone in humans. Here, we used positron emission tomography (PET) and the D3 -preferring probe, [11C]-(+)-PHNO, to test the hypothesis that buspirone will occupy (decreases [11C]-(+)-PHNO binding) the DRD3 more readily than the DRD2. Eight healthy participants underwent [11C]-(+)-PHNO scans after single oral dose administration of placebo and 30, 60, and 120 mg of buspirone in a single-blind within-subjects design. [11C]-(+)-PHNO binding in DRD2- and DRD3-rich areas was decreased by the highest (60-120 mg), but not the lowest (30 mg), doses of buspirone. The maximal occupancy obtained was ∼25% in both areas. Plasma levels of prolactin (a DRD2 marker) correlated with percentage occupancy after orally administered buspirone. Self-reported dizziness and drowsiness increased after buspirone but that did not correlate with receptor occupancy in any region. Overall, the modest occupancy of DRD2 and DRD3 even at high acute doses of buspirone, yielding high levels of metabolites, suggests that buspirone may not be a good drug to preferentially block DRD3 in humans.

UR - http://www.scopus.com/inward/record.url?scp=84949551585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949551585&partnerID=8YFLogxK

U2 - 10.1038/npp.2015.177

DO - 10.1038/npp.2015.177

M3 - Article

VL - 41

SP - 529

EP - 537

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -